Delivery Order SPE2DR25D3501-SPE2DR26FM1EA
Award Date 12/23/25
Potential Completion Date 12/24/25
Potential Value $6.5K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency awarded a delivery order valued at $1,830.91 to AmerisourceBergen Drug Corp for Ruxience 500 mg/50 mL vials on November 13, 2025, with completion by November 14, 2025. Ruxience is a biosimilar to rituximab used in treating various cancers and autoimmune conditions. This competitively awarded, firm fixed-price contract carries no set-aside designation and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on December 8, 2025, for the supply of Ruxience 500 mg/50 mL vials with a ceiling value of $9,901.80. This is a firm fixed price, competitively awarded contract with no set-aside designation and an ultimate completion date of December 9, 2025. Ruxience is a biosimilar to rituximab used in treating various cancers and autoimmune conditions. The contract is performed at AmerisourceBergen's Corporate Office...
- The Defense Logistics Agency awarded a delivery order valued at $15,015.87 to AmerisourceBergen Drug Corp for Ruxience 500 mg/50 mL vials on August 7, 2025, with an ultimate completion date of August 8, 2025. This competitively awarded, firm fixed-price contract represents a non-set-aside procurement and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Ruxience is a biosimilar to rituximab used in treating various cancers and autoimmune conditions,...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $25,262.82 delivery order for Ruxience 500 mg/50 mL vials on September 25, 2025, with completion targeted for September 26, 2025. This firm fixed-price contract represents a non-competed award under an existing vehicle and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. Ruxience is a biosimilar to rituximab used in the treatment of various cancers and autoimmune conditions, reflecting...
- The Defense Logistics Agency awarded a delivery order valued at $4,950.90 to AmerisourceBergen Drug Corp for Ruxience 500 mg/50 ml vials on October 29, 2025, with completion expected by October 30, 2025. This firm fixed price delivery order represents a competitive award with no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Ruxience is a biosimilar to rituximab used in treating various cancers and autoimmune conditions, reflecting the...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Ruxience 500 mg/50 ml vials valued at $5,969.24 under a firm fixed-price contract type. Ruxience is a biosimilar to rituximab, used in treating various cancers and autoimmune conditions. The delivery order carries an ultimate completion date of August 11, 2025, and will be performed at AmerisourceBergen's Conshohocken, Pennsylvania headquarters. This award represents a...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded AmerisourceBergen Drug Corp a delivery order valued at $11,951.84 for RUXIENCE 500 mg/50 ml vials on August 19, 2025, with completion scheduled for August 20, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. RUXIENCE is a biosimilar to rituximab used in the treatment of various cancers...
- The Defense Logistics Agency awarded a delivery order valued at $1,939.51 to AmerisourceBergen Drug Corp for Ruxience 500 mg/50 ml vials on December 15, 2025, with completion scheduled for December 16, 2025. This competitively awarded, firm fixed-price order represents a continuation of the company's substantial pharmaceutical supply relationship with DLA. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Ruxience 500 mg/50 ml vials, a biosimilar to rituximab used in oncology and immunology treatments. This firm fixed-price delivery order, valued at $4,950.90, was awarded on November 24, 2025, with an ultimate completion date of November 25, 2025, and represents a non-set-aside competitive award. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency awarded a delivery order valued at $1,956.88 to AmerisourceBergen Drug Corp for RUXIENCE 500 mg/50 mL vials on August 4, 2025, with completion expected by August 5, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. RUXIENCE is a biosimilar to rituximab used for treating various cancers and autoimmune conditions,...